Abstract:
To evaluate the results of rheumatoid arthritis treatment using the immunomodulator erixin. Material
and methods: 60 patients were observed who were treated in outpatient and inpatient settings at the Republican Center for Rheumatology, the specialized arthrology outpatient department, the therapeutic and nephrology departments
of the multidisciplinary clinic of the Tashkent Medical Academy in 2023-2024. 30 patients of the 1st group received
basic treatment, 30 patients of the 2nd group received intravenous immunomodulator erixin against the background
of basic treatment. Results: The study examined clinical, laboratory and immunological parameters of patients with
rheumatoid arthritis. The treatment results were compared using the VASH scale, DAS 28 index and a number of immunological parameters. Positive changes were observed in patients of both groups, however, patients who received
basic anti-inflammatory drugs and erixin injections managed to achieve clinical remission of the disease. Conclusions:
Basic treatment of rheumatoid arthritis with the inclusion of the immunomodulator erixin allows achieving clinical
remission in a shorter time.
